Exploring New Treatments for Autoimmune Diseases

A new grant will allow Michigan Medicine researchers to explore personalized approaches to treating autoimmune diseases such as scleroderma, lupus, rheumatoid arthritis and others.

2:49 PM

Author | Kylie Urban

auto immune image
Skin fibroblasts isolated from a scleroderma patient. The red fluorescence is staining alpha-smooth muscle actin, a myofibroblast marker usually seen in high levels in these patients. These activated cells are the culprit in scleroderma fibrosis.

More than 50 million Americans are affected by an autoimmune disease, with women at an increased risk for developing one.  

"Autoimmune conditions can be debilitating for patients," says Dinesh Khanna, M.D., M.Sc., a professor of rheumatology and the director of the Michigan Medicine Scleroderma Program.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher.

"As a National Institutes of Health Autoimmunity Center of Excellence site, we have the opportunity at Michigan Medicine to conduct extensive translational research, in a clinical trial setting, on autoimmune diseases which allows us to provide the newest, targeted and personalized therapies to our patients."

Khanna and his fellow rheumatology colleagues, J. Michelle Kahlenberg, M.D., Ph.D., and David Fox, M.D., were awarded a grant, up to $10.2 million, by the Autoimmunity Centers of Excellence to explore three new projects for potential treatments of autoimmune diseases.

"I will be leading the project on scleroderma, Dr. Kahlenberg will lead a project on lupus and Dr. Fox will lead a collaborative project where we will study a broad range of other autoimmune diseases," says Khanna, who is a co-principal investigator of the grant with Fox.

New projects

While new treatments for autoimmune conditions may help patients with some of their symptoms, they often lead to impairment of normal immune system functions, leaving many patients more susceptible to infections. The research team will study how molecular targets affect autoimmune inflammation and damage, and how to avoid impairing the immune system's ability to fight infection.

We have the opportunity at Michigan Medicine to conduct extensive translational research, in a clinical trial setting, on autoimmune diseases which allows us to provide the newest, targeted and personalized therapies to our patients.
Dinesh Khanna, M.D., M.Sc.

In the scleroderma project, Khanna will test the drug elotuzumab, already approved by the U.S. Food and Drug Administration for treatment of the blood cancer multiple myeloma, as a potential treatment for patients with scleroderma.

"The trial design will recruit patients with early scleroderma who have elevated levels of abnormal lymphocytes, CD4+ cytotoxic T cells, in the blood," Khanna says. "The project will be a safety trial, and we hope it can open a new treatment option for patients affected with scleroderma, a disease without FDA approved therapies."

In the lupus project, Kahlenberg, an associate professor of rheumatology, will test the drug, tofacitinib, currently approved to treat rheumatoid and psoriatic arthritis, in cutaneous lupus.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs. Those affected experience inflammation throughout the body, as well as fatigue.

She has previously studied a signaling protein tied to UV light sensitivity in patients with lupus. This project will build upon that work and provide further proof that blocking the protein's pathway can provide protection from UV light. Kahlenberg will also study the role tofacitinib plays in the protein signaling.

"We're hoping to provide more targeted and less toxic therapies for our lupus patients," she says.

In the final project, Fox will explore new molecular targets in a range of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, lupus, scleroderma and autoimmune eye diseases.

"This project will be an opportunity to take new discoveries related to rheumatoid arthritis and apply this progress to the study of many other autoimmune diseases that affect multiple organs and tissues in our patients, with the ultimate goal of safer and more effective treatment," Fox says.

Future results

The researchers are excited for the projects to get underway and hope to have results in the next three to five years.

"We're constantly exploring new treatment options for our patients with autoimmune diseases," Khanna says.

"Grants, such as this one, help us take our work from the lab and translate it into tangible benefits for the patients we see each day in clinic."

This work will be performed under the University of Michigan Clinical Autoimmunity Center of Excellence, grant number AWD012101, funded by the NIH-NIAID.


More Articles About: Lab Report Arthritis Lupus Rheumatology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Woman sleeping on a couch holds her stomach, as if in pain
Health Lab
Long COVID-19 is linked to chronic pain conditions
Therapies for pain conditions like fibromyalgia provide clues for helping those with long COVID-19
vial of blood in container lab blue yellow grainy graphic
Health Lab
Unveiling potential diagnostic, treatment target for APS-related thrombocytopenia
Researchers at the University of Michigan Health have unveiled a new mechanism that drives thrombocytopenia and a potential clinically actionable biomarker for antiphospholipid syndrome associated thrombocytopenia.
Illustration of hand and enzymes that affect scleroderma patients
Health Lab
Novel antibody targets CD38 enzyme to treat systemic sclerosis
New study has identified an enzyme contributing to systemic sclerosis.
doctor with patient white and black patient ignored
Health Lab
Fixing racial inequities in lupus care
When it comes to lupus care, Black adults are normally left behind despite being one of the highest lupus populations.
red lines with heart through it beige background
Health Lab
Research finds potential target for cardiovascular disease in diabetes
University of Michigan researchers found that the overproduction of neutrophil extracellular traps is an important contributing factor to vascular dysfunction in diabetes.
ginger bunch
Health Lab
Could ginger help treat autoimmune disease symptoms?
Michigan Medicine researchers are examining whether ginger supplements could help treat symptoms in autoimmune diseases